Tylenol maker Kenvue's CEO quits amid board's strategic review
unknown📝 Article Content
Shares of the Tylenol maker rose 3.3% in premarket trading as it named company director Kirk Perry as interim CEO. The company had in May replaced finance chief Paul Ruh with Kellanova's Amit Banati. Kenvue, which was spun off from Johnson & Johnson in 2023, has been looking to improve profitability, particularly in its skin-health and beauty unit, which includes brands such as Neutrogena and Aveeno.
📄 Summary
Shares of the Tylenol maker rose 3.3% in premarket trading as it named company director Kirk Perry as interim CEO. The company had in May replaced finance chief Paul Ruh with Kellanova's Amit Banati. Kenvue, which was spun off from Johnson & Johnson in 2023, has been looking to improve profitability, particularly in its skin-health and beauty unit, which includes brands such as Neutrogena and Aveeno.